[The concept of innovative drugs rebounded in shock, and Smart Medicine and Bide Medicine rose by more than 10%] On October 30, the concept of innovative drugs rebounded in shock during the session. Smart Medicine and Bide Medicine rose by more than 10%, followed by Haoyuan Pharmaceutical, Wanbang Pharmaceutical, Baihua Pharmaceutical, Qianhong Pharmaceutical, etc. On the news, on October 29, US biopharmaceutical giant Eli Lilly announced that its net profit in the third quarter of 2026 was US$6.451 billion, a year-on-year increase of 16%, and its performance was higher than market expectations. The revenue of Mounjaro and Zepbound, related products of the weight loss and diabetes drug Tilpotide, increased by 65% ​​and 49% respectively. The company raised its full-year revenue guidance to $91 billion to $92 billion.